Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2022 07:30 ET | Source: Arch Biopartners

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
January 04, 2022 07:25 ET | Source: Arch Biopartners

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
May 04, 2021 07:00 ET | Source: Arch Biopartners

Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
October 16, 2020 07:00 ET | Source: Arch Biopartners

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial...